How TTIP could damage access to affordable medicines in the European Union

What’s the “big deal”? 
The European Union (EU) and United States (US) are negotiating the Transatlantic Trade and Investment Partnership (TTIP). Under the deal, we’ll pay more for our medicines—and know less about them. TTIP will also set a new standard for other trade deals worldwide.

What if TTIP is approved?

US pharma companies could sue Member States for lost profits if they try to decrease medicine prices or prevent unsafe or ineffective medicines from entering the market. We’ll get less money back for the medicines we buy and will pay higher taxes to cover lawsuits and rising healthcare costs.

Public access to important information on the safety and effectiveness of medicines could be restricted. We won’t know the true risks and benefits of the medicines we take.

Patent periods for new drugs could be extended, which delays generic competition. We’ll pay high monopoly prices for medicines for a longer period of time.

What can the EU do?

Rid TTIP of investor-state dispute settlement.

Guarantee open access to clinical trial data.

Support generic competition.

Allow Member States to tailor their own national medicines policies.

Don’t let Big Pharma set national health agendas.

Put patient safety first.

Don’t extend Big Pharma’s monopoly protection period.

Help governments ensure safe and affordable medicines.

Learn more: bit.ly/HealthOverWealth

Get involved: #A18DoA #TTIP #HealthOverWealth